{"entity":{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","aka":["Clovis Oncology, Inc."],"tldr":"Clovis Oncology was the Colorado company that brought the PARP inhibitor rucaparib (Rubraca) to market for ovarian and prostate cancer before filing for bankruptcy in December 2022; its products passed to pharma& in 2023.","summary":"Clovis Oncology, based in Boulder, Colorado and listed on Nasdaq, developed rucaparib (Rubraca), a PARP inhibitor approved in the United States from 2016 for BRCA-mutated ovarian cancer, then as maintenance therapy (ARIEL3) and for BRCA-mutated metastatic castration-resistant prostate cancer (TRITON2). An earlier lead, the EGFR inhibitor rociletinib, was abandoned in 2016 after disputed response data. Competition from other PARP inhibitors and a restricted label left the company unable to service its debt; it filed for Chapter 11 in December 2022 and sold Rubraca to pharma& in 2023. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Clovis_Oncology","links":[{"label":"ClinicalTrials.gov: trials led by Clovis Oncology","url":"https://clinicaltrials.gov/search?lead=Clovis%20Oncology"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Clovis_Oncology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","prostate"],"sections":["targeted-therapy"],"technologies":[],"targets":["parp"],"drugs":["rucaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03899155"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Boulder, CO","country":"US","companyType":"biotech","website":"https://www.clovisoncology.com","stage":"defunct","investors":[],"funding":[]},"route":"/companies/clovis-oncology/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/"}],"trial":[{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/"},{"id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","route":"/trials/nct03899155/"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/"}],"paper":[{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/"},{"id":"paper-fizazi-triton3-rucaparib-nejm-2023","kind":"paper","name":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/"}],"company":[{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/"}]}}